 "pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing")
The production-linked incentive (PLI) scheme to boost local manufacturing of bulk drugs or ingredients to make medicines has been revised, making it more industry friendly.
Industry sources say that while not all their recommendations have been accepted by the Centre, the changes to the scheme nonetheless will encourage more micro, small and medium enterprises (MSMEs) to come forward now.
The most significant change to the scheme is the removal of the minimum investment criterion to be eligible for the incentive, replacing it instead with a minimum production volume for each of the products identified under the scheme.
Also, the government
